This November election will mark a “tipping point” for cannabis legalization in the United States, a consultation firm predicted Tuesday. “The interesting thing about a tipping point is you never really see it coming,” “In the world of marijuana, we are at those tipping point days. Says, a deep-pocketed Orlando attorney, who has spent roughly $7.5 million of his own money on this November’s MMJ ballot initiative in Florida as well as a failed 2014 effort.

“There is no state in the union that is more ready for this industry than Florida,” He says.

His comments come as a slew of states could – or will – vote on legalizing recreational marijuana in November, including: California, Maine, Massachusetts, Nevada, Michigan, and Arizona. Other than Florida, voters in Missouri and Ohio could pass judgement on MMJ legalization.

“This is a global cannabis movement. If California passes, that’s going to ripple across the globe,” said a CEO of a consulting firm in California.

According to another consultant, sales for the California recreational market alone would exceed the existing level of nationwide sales for both medical and recreational cannabis. Who compared a “tipping point” with a snowflake hitting a mountain. And then there’s this avalanche,” he added. “And you go, my god, it was just a snowflake. No. It was years and years of built-up snow and pent-up energy just waiting for that one snowflake” A great candid style and blunt observation from one if I do say so myself!

We are also seeing investors who are spending $$ for these initiatives on the ballot due to many who have family members that may have terminal illness, or who are quadriplegic and use cannabis to help cope with their symptoms.

One Investor has learned several lessons from the near-passage of MMJ at the Florida ballot box in 2014. The campaign is applying those lessons this time around.

A Florida campaign with ties to casino mogul Sheldon Adelson – who helped defeat the 2014 medical cannabis initiative in the Sunshine State – plans to raise at least $10 million to fight MMJ legalization this fall.

The real opposition to legalizing medical cannabis, some say is coming from pharmaceutical companies.

“Who has the most to lose?” …Big Pharma.”

If the Florida MMJ initiative is approved, an estimated 400,000-500,000 patients in Florida will be able to obtain legal relief from marijuana. That’s a sizable customer base for any would-be company in the Sunshine State, and any company that sticks with the cannabis trade will come out a winner.

“You all, who are in this marijuana business, if you stay with it for the long haul, are going to make a small fortune,” he said. “You’re also going to do a great thing, because you’re going to employ people who are losing jobs to technology, that can be future Bud-Tenders or Bud-Leaf Trimming Operators. Get in Line!

Michael Garay ~

GMP refers to the Good Manufacturing Practice Regulations promulgated by the US Food and Drug Administration under the authority of the Federal Food, Drug, and Cosmetic Act (See Chapter IV for food, and Chapter V, Subchapters A, B, C, D, and E for drugs and devices.) These regulations, which have the force of law, require that manufacturers, processors, and packagers of drugs, medical devices, some food, and blood take proactive steps to ensure that their products are safe, pure, and effective. GMP regulations require a quality approach to manufacturing, enabling companies to minimize or eliminate instances of contamination, mixups, and errors. This in turn, protects the consumer from purchasing a product which is not effective or even dangerous. Failure of firms to comply with GMP regulations can result in very serious consequences including recall, seizure, fines, and jail time.

GMP regulations address issues including record keeping, personnel qualifications, sanitation, cleanliness, equipment verification, process validation, and complaint handling. Most GMP requirements are very general and open-ended, allowing each manufacturer to decide individually how to best implement the necessary controls. This provides much flexibility, but also requires that the manufacturer interpret the requirements in a manner which makes sense for each individual business.

GMP is also sometimes referred to as “cGMP”. The “c” stands for “current,” reminding manufacturers that they must employ technologies and systems which are up-to-date in order to comply with the regulation.